4.8 Article

Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

Comparison of IVIg 5% Versus 10% in hematological patients with a secondary immunodeficiency disorder

Jonas van Ham et al.

Summary: The study aimed to evaluate the administration of 5% vs. 10% IVIg solutions in hematological patients with SID. Results showed that using a 10% IVIg solution significantly reduced infusion time and total duration of the day clinic visit. However, caution must be taken to minimize new infusion-related adverse events. Switching to a 10% IVIg administration increased patient and nursing satisfaction, but additional workflow changes are needed to further shorten the day clinic visit.

ACTA CLINICA BELGICA (2021)

Article Immunology

Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin

Hossein Esmaeilzadeh et al.

Summary: This study assessed the adverse reactions of IVIg infusions in IEI patients in Iran, finding that almost half of the patients experience adverse reactions mainly during the first infusion, with common symptoms including myalgia, chills, headache, fever, and hypotension. Therefore, close observation is necessary for IEI patients receiving IVIg treatment.

CLINICAL IMMUNOLOGY (2021)

Article Immunology

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

Elena E. Perez et al.

Summary: The study demonstrated that GC5107 is an effective, safe, and well-tolerated treatment for patients with primary immunodeficiency in preventing serious bacterial infections. One acute serious bacterial infection occurred during the 12-month study period, with low incidence rates of other infections and hospitalizations. The medication was well-tolerated with few adverse events reported.

FRONTIERS IN IMMUNOLOGY (2021)

Article Immunology

A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion

Hidefumi Kato et al.

Summary: This study found that risk factors for adverse reactions associated with IVIG therapy include female sex, adult age, high dose IVIG, autoimmune disease, and neuromuscular disease. Multivariate logistic regression identified neuromuscular disease as a significant factor for adverse reactions to IVIG.

FRONTIERS IN IMMUNOLOGY (2021)

Article Clinical Neurology

Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases

Jonas Graf et al.

ACTA NEUROLOGICA SCANDINAVICA (2019)

Review Immunology

Adverse Effects of Immunoglobulin Therapy

Yi Guo et al.

FRONTIERS IN IMMUNOLOGY (2018)

Review Allergy

Update on the use of immunoglobulin in human disease: A review of evidence

Elena E. Perez et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)

Article Immunology

Efficacy and safety of Gammaplex® 5% in children and adolescents with primary immunodeficiency diseases

I. R. Melamed et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)

Review Pharmacology & Pharmacy

Evidence-Based Strategies to Reduce Intravenous Immunoglobulin-Induced Headaches

Krisy-Ann Thornby et al.

ANNALS OF PHARMACOTHERAPY (2015)

Editorial Material Allergy

Practice parameter for the diagnosis and management of primary immunodeficiency

Francisco A. Bonilla et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)

Article Allergy

Clinical picture and treatment of 2212 patients with common variable immunodeficiency

Benjamin Gathmann et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)

Article Immunology

Kiovig for primary immunodeficiency: Reduced infusion and decreased costs per infusion

Mark Connolly et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2011)

Article Immunology

Intravenous immunoglobulins - understanding properties and mechanisms

A. Durandy et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)